广生堂：预计2025年亏损1.7亿元-2.4亿元

Core Viewpoint - The company Guangshentang (300436) has announced a projected net loss for 2025, estimating a loss between 170 million to 240 million yuan, compared to a loss of 156 million yuan in the previous year [4] Financial Performance - The projected net profit for 2025 is expected to be a loss of 1.7 billion to 2.4 billion yuan, with a non-recurring net profit loss estimated at 1.78 billion to 2.48 billion yuan, compared to a loss of 2 billion yuan in the previous year [4] - The company's price-to-book ratio (LF) is approximately 41.43 times, and the price-to-sales ratio (TTM) is about 36.83 times [4] - Historical net profit and non-recurring profit figures show a consistent trend of losses over the years, with the projected figures for 2025 indicating a continuation of this trend [6][7] Research and Development - The company maintains a focus on innovative drug development, with significant investments in research and clinical trials, particularly for the hepatitis B treatment drug GST-HG141, which has completed enrollment of 526 participants in its Phase III clinical trial [5] - The company anticipates completing the enrollment by mid-February 2026, with a potential slight increase in the final number of participants [5] - The company has conducted impairment tests on intangible assets, inventory, and fixed assets, leading to a projected impact of approximately 7.5 million yuan from non-recurring gains and losses, a decrease of about 35.73 million yuan year-on-year, primarily due to a significant reduction in government subsidies [5]